Your browser is no longer supported. Please, upgrade your browser.
Settings
TAK Takeda Pharmaceutical Company Limited daily Stock Chart
TAK [NYSE]
Takeda Pharmaceutical Company Limited
Index- P/E24.66 EPS (ttm)0.81 Insider Own38.80% Shs Outstand3.15B Perf Week0.45%
Market Cap63.09B Forward P/E14.40 EPS next Y1.39 Insider Trans0.00% Shs Float3.00B Perf Month-1.43%
Income- PEG91.33 EPS next Q0.35 Inst Own- Short Float0.13% Perf Quarter14.15%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio3.54 Perf Half Y15.13%
Book/sh12.55 P/B1.59 EPS next Y- ROA- Target Price24.20 Perf Year1.94%
Cash/sh- P/C- EPS next 5Y0.27% ROE- 52W Range16.10 - 21.61 Perf YTD1.42%
Dividend0.83 P/FCF- EPS past 5Y- ROI- 52W High-7.40% Beta-
Dividend %4.15% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low24.29% ATR0.21
Employees49578 Current Ratio- Sales Q/Q88.30% Oper. Margin- RSI (14)49.37 Volatility1.02% 0.95%
OptionableYes Debt/Eq- EPS Q/Q11.20% Profit Margin- Rel Volume0.87 Prev Close20.06
ShortableYes LT Debt/Eq- EarningsJan 31 BMO Payout- Avg Volume1.08M Price20.01
Recom2.00 SMA200.48% SMA50-0.43% SMA2009.48% Volume942,563 Change-0.25%
Nov-01-19Initiated Cowen Market Perform $19.50
Aug-15-19Downgrade Daiwa Securities Outperform → Neutral
Jan-17-20 03:34PM  Still Time to Ride the Wave With Charles River GuruFocus.com
Jan-14-20 06:00AM  Takeda to Outline Progress on Business Transformation and Priorities at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-05-20 05:14PM  Despite Recent Gains, Mirium Shares Still Rated a Buy GuruFocus.com
Jan-01-20 05:00AM  ADHD app: game theory Financial Times
Dec-31-19 06:10AM  Experts question Cambridge biotech's strategy after trial failure American City Business Journals
Dec-30-19 04:10PM  Why This Biotech Stock Had Two Devastating Crashes This Month Investor's Business Daily
Dec-27-19 03:46PM  Hedge Fund Consensus Stocks vs. Takeda Pharmaceutical Company Limited (TAK) In 2019 Insider Monkey
Dec-19-19 08:00AM  Takeda Makes Bet on Viral Cancer-Killers in Deal With Turnstone Bloomberg
Dec-17-19 09:00PM  Japan's exports shrink for 12th month as U.S., China demand falls Reuters
Dec-16-19 09:27AM  Cambridge biotech's stock price tumbles on Duchenne drug failure American City Business Journals
Dec-14-19 04:47PM  Biotech stocks are producing outsized gains heres how to get your share MarketWatch
Dec-13-19 03:05PM  Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool to Redefine Crohn's Disease Management PR Newswire
Dec-09-19 10:00AM  Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019 Business Wire
10:00AM  Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting Business Wire
Dec-07-19 09:30AM  Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis Business Wire
Dec-06-19 03:07PM  Brandes Investments' Top 5 Buys in the 3rd Quarter GuruFocus.com
Dec-04-19 08:02PM  Is Takeda Pharmaceutical Company Limited (TAK) A Good Stock To Buy? Insider Monkey
Nov-25-19 08:38AM  Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting Business Wire
Nov-23-19 12:14PM  Longer-term data fail to clear concern over Takeda's dengue vaccine Reuters
10:30AM  Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting Business Wire
Nov-22-19 10:00PM  Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up Business Wire
10:00PM  CORRECTED-Takeda says cancer drug Alunbrig shows longer benefit vs crizotinib Reuters
10:16AM  Investors Hope for More From Takeda Than a Healthy Dividend GuruFocus.com
Nov-20-19 09:22AM  Myovant Up on Successful Completion of Prostate Cancer Study Zacks
Nov-14-19 01:27PM  Sarepta expands gene therapy push with $90M deal American City Business Journals
06:00AM  Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day Business Wire
Nov-13-19 09:06AM  Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3 Zacks
Nov-11-19 09:28AM  4 Biotech Stocks That Could Keep Beating Wall Street Zacks
Nov-08-19 07:58AM  New Analyses from the Phase 3 HELP Study Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period Business Wire
Nov-07-19 11:23AM  Takeda Takes a Big Step Into New Cancer Immunotherapy GuruFocus.com
08:00AM  Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation Business Wire
Nov-06-19 10:58PM  UPDATE 1-Takeda's dengue vaccine effective overall in study but with major limitation Reuters
05:00PM  Takeda's dengue vaccine effective overall in study but with major limitation Reuters
05:00PM  Takedas Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure Business Wire
12:00PM  Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting Business Wire
Nov-05-19 09:00AM  Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany Business Wire
07:00AM  Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform Business Wire
06:53AM  The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga
02:00AM  Takeda Continues Strategic Divestitures With Sale of Select OTC and Non-Core Assets to STADA for $660 Million USD Business Wire
Oct-31-19 02:00AM  Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance for the Full Year Business Wire
Oct-30-19 12:29PM  Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark Zacks
08:17AM  Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial American City Business Journals
Oct-28-19 09:05AM  First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes: Takeda's Investigational Therapy Meets Co-Primary & Key Secondary Efficacy Endpoints PR Newswire
Oct-22-19 07:51AM  The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug Benzinga
01:00AM  Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study Business Wire
Oct-21-19 01:00AM  Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohns Disease Business Wire
Oct-18-19 06:30AM  Takeda pares down products and jobs, revives Genzyme building plans American City Business Journals
Oct-15-19 07:50AM  The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings Benzinga
04:08AM  UPDATE 1-Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino Reuters
03:36AM  Takeda sells Mideast, Africa drugs to Switzerland's Acino for around $200 mln Reuters
02:45AM  Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD Business Wire
Oct-11-19 09:37AM  Easy Investing Secrets to an Early Retirement - October 11, 2019 Zacks
05:07AM  Takeda Nears Russia, Mideast Asset Sale to Private Equity Bloomberg
Oct-10-19 11:24AM  Should You Avoid Takeda Pharmaceutical Company Limited (TAK)? Insider Monkey
Oct-09-19 09:39AM  Signs That Your Trading Will Ruin Your Retirement - October 09, 2019 Zacks
Oct-03-19 05:30PM  Here Is Hedge Funds 22nd Most Popular Stock Pick Insider Monkey
03:49PM  Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar Benzinga
Oct-01-19 06:56PM  As Buyout Fever Grows, Alexion, Amarion and BioMarin Are Potential Targets GuruFocus.com
Sep-26-19 02:28PM  Takeda Is Close to Selling Emerging Market, European Drugs Bloomberg
07:54AM  The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J Benzinga
Sep-25-19 08:15PM  New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1 Business Wire
05:00PM  First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab Business Wire
Sep-24-19 07:00AM  New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takedas TAK-620 (Maribavir) as a Potential Treatment of Cytomegalovirus (CMV) Infection Business Wire
Sep-23-19 07:17PM  Investors May Want to Follow the Progress of These Biotechs GuruFocus.com
Sep-19-19 01:00AM  Takeda Recognized in the 2019 Dow Jones Sustainability World Index Business Wire
Sep-18-19 04:30AM  NICE Recommends Takhzyro®(Lanadelumab) for the Treatment of People Living with Rare Debilitating Genetic Disorder PR Newswire
Sep-17-19 10:39AM  Karyopharm Signs $150M Royalty Agreement to Support Xpovio Zacks
Sep-06-19 07:27AM  The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication Benzinga
Sep-05-19 05:59PM  Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate PR Newswire
05:11PM  Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate CNW Group
Aug-21-19 08:40PM  Somerville's Finch raises $53M to develop bacteria pills for C.diff, autism American City Business Journals
Aug-16-19 09:30AM  Is Takeda (TAK) a Profitable Stock for Value Investors Now? Zacks
Jul-31-19 02:00AM  Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year Business Wire
02:00AM  Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration Business Wire
Jul-24-19 03:29PM  How Do Earnings Impact The Stock Market? Zacks
Jul-23-19 10:18AM  The AbbVie-Allergan Merger Is the Most Positive of the Pharma Deals Barrons.com
Jul-22-19 01:00AM  Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease Business Wire
Jul-17-19 12:57PM  Takeda kicks off sale of Western European drugs: sources Reuters
10:58AM  Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates Zacks
Jul-16-19 01:15PM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-15-19 05:59PM  J&J Submits BLA for Subcutaneous Formulation of Darzalex Zacks
Jul-09-19 09:00PM  Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index Business Wire
02:15PM  Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation of Takeda Pharmaceutical Company Ltd. (TAK) ACCESSWIRE
11:30AM  ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-08-19 02:00AM  Takeda Unveil New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalized Prophylaxis with ADYNOVATE in Severe Hemophilia A Business Wire
Jul-03-19 09:50AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK) ACCESSWIRE
07:00AM  Takeda to Demonstrate Global Leadership in Hematology at ISTH 2019 Business Wire
Jul-02-19 11:53AM  Marshall Waces Return, AUM, and Holdings (Part II) Insider Monkey
11:30AM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-01-19 04:31PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK GlobeNewswire
02:20PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK) ACCESSWIRE
11:30AM  Takeda Completes Sale of Xiidra® to Novartis Business Wire
09:26AM  Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status Zacks
Jun-28-19 08:00PM  AbbVie Is Buying Allergan. Thats Not the Right Remedy for the Stock. Barrons.com
04:01PM  J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma Zacks
03:20PM  SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:13PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK PR Newswire
03:13PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK CNW Group
01:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK ACCESSWIRE
02:00AM  Pharma-owned plasma center set for major expansion in metro Phoenix American City Business Journals
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers medicines in various therapeutic areas, including gastroenterology; cancer; neurological and psychiatric diseases; and rare diseases, such as immunology and hematology, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., and Sosei Group Corporation; strategic collaboration with Prometheus Biosciences, Inc; license and research agreement with The University of Texas MD Anderson Cancer Center; and research collaboration agreements with Enzyre BV and Cerevance. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.